Spruce Biosciences Free Cash Flow (FCF) History (SPRB)

Spruce Biosciences reported −$56.0M in free cash flow for fiscal 2024, a decrease of $22.7M from the previous fiscal year, with a free cash flow margin of −1139.56%.

View full Spruce Biosciences company overview

Spruce Biosciences free cash flow by year

Spruce Biosciences annual free cash flow

Fiscal yearPeriod endedFree cash flowChangeGrowthFCF margin
20242024-12-31−$56.0M−$22.7M−1139.56%
20232023-12-31−$33.3M$8.4M−329.88%
20222022-12-31−$41.7M−$5.7M
20212021-12-31−$36.0M−$8.4M
20202020-12-31−$27.6M−$15.0M
20192019-12-31−$12.6M

Spruce Biosciences free cash flow growth trends

Over the last five reported fiscal years, free cash flow declined from −$12.6M to −$56.0M, a net decrease of $43.3M. Spruce Biosciences's latest reported quarter, Q2 2026, generated −$22.3M in free cash flow, a decrease of $10.0M year over year.

About the metric

What free cash flow means

Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.

Calculation and source

How free cash flow is calculated

TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.

Review Spruce Biosciences filings at SEC.gov ↗